Hims & Hers Stock Rises Amid App Download Surge

Hims & Hers sees a 2.2% stock jump as app downloads rise 47% year-over-year in February. While this suggests strong user growth, future viability may be at risk due to FDA regulations. Analysts keep a cautious stance with an 'equal weight' rating.

Date: 18-03-2025

AI Rating: 5

Hims & Hers Health has experienced a positive impact on stock prices, attributed to a significant 47% year-over-year increase in app downloads reported by Morgan Stanley. This growth indicates potential new customer acquisition, primarily from female users, as seen through their offerings related to health and wellness.

However, there are factors indicating potential negative repercussions for future stock performance. The report mentions concerns regarding FDA regulations that might prohibit Hims & Hers from selling specific GLP-1 drugs, particularly as there is no longer deemed to be a deficiency in these drugs from major manufacturers. This could hinder the company’s revenue, as an increase in app downloads may not translate into ongoing customer retention or sales if the drugs become unavailable.

Despite the current positive momentum with increased downloads, the analyst maintained a cautious outlook, preserving a price target of $60 while advising against an upgrade. The stock currently trades at a high earnings multiple (P/E of 62), and any projected rise to $60 would further inflate this ratio beyond 100, suggesting overvaluation concerns.

In summary, while the current app download surge paints a picture of potential growth, the looming regulatory issues and valuation concerns caution investors. A reliance on transient promotional factors such as major sporting events could also impact sustained demand for Hims & Hers offerings in the future.

Stocks: HIMS AAPL NVO LLY